Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

  • 00:50

    How Investors Assess R&D Biotech Management

    in Science

    At the May 2015 Chief Medical Officer's Summit in Boston, we featured a session on:


    How Investors Assess R&D Biotech Management
    Take a look at the details below:
    In this session, we begin with a presentation on a perspective on the method of evaluating a disease space, which includes a comprehensive understanding of 1) the science, 2) the competitive landscape and 3) the management teams for each company. How does this get mapped out?
    Following will be more discussion on:
    Understanding the context of value proposition
    Strategic fit
    Processes used to evaluate management and an understanding of competitive strategy
    How best to convey your plans
    How best to communicate with investors (before investment) and boards (afterwards) – via the CEO or directly?
    Importance of clinical development plan expectations
    Moderated by: Peter Kolchinsky, PhD Managing Director, RA Capital Management, LLC
    Panelists: Jonathan Behr, PhD EIR and Market Sector Leader, Innovation, Partners Healthcare, David Berry, MD, PhD Partner, Flagship Ventures, Vikas Goyal, MBA Principal, SR One, and Jeffrey Moore, DPhil, MBA President, MPH Venture Management
    The next CMO Summit is November 9-10 in Burlingame, California. It is one of the best face-to-face opportunities for R&D leaders in emerging biotechs to:
    1. Address the unique challenges associated with directing and managing all R&D functions with limited resources, while raising capital, working and meeting with investors, and strategizing for appropriate exits. 2. To create a network of CMOs & other R&D leaders from small to midsize life science companies to share ideas, solutions and support.


    For information, visit www.theconferenceforum.org


    Partial and full scholarships available for start-ups.

  • 00:26

    JAMIE GROOMS: BIOTECH LEADER

    in Entrepreneur

    How do you know when changes in the market help you pivot to a better solution?


    Ask Jamie Grooms. He is the CEO of the Florida Institute for the Commercialization of Public Research, a non-profit organization that assists new companies during their creation process. The institute leverages $2 billion of research funding to assist companies that will impact the global marketplace with scientific breakthroughs.


    A major innovator in the biotech field, Jaime moved from a position of middle management at the Tissue Bank of the University of Florida, to become the CEO of Regeneration Technologies virtually overnight. That company, now known as RTI Biologics, is a global leader in implants from donor tissue.


    “It’s not what you plan; it’s what you can see as an opportunity,” Jamie notes. His original plan was to use advanced bone implant technology in the sports medicine market, but sales weren’t matching expectations. So he re-examined his assumptions and pivoted into the spinal implant market, where his product was greeted enthusiastically on the basis of a strong pre-existing. This allowed him to make a greater impact on the market, which led to huge profits for Jamie and his team.


    Success and expansion come with their own challenges. Jamie admits that at first he had trouble adapting to his sudden CEO status, (a position he defines as “the ultimate middle management service provider.”) He sought recommendations for an executive coach who taught to trust and develop his own brand of leadership. His ability to learn and adapt keeps Jamie at the frontline of the biotech field. What challenges are you facing as your brand expands?

  • 00:13

    The Biotech Giant You’ve Never Heard Of

    in Finance

    CVS Health shares drop, despite strong Q2 profits. Regeneron Pharmaceuticals, the $60-billion biotech, hits an all-time high.  We discuss how to start investing in biotechnology stocks, and why Tommy’s Pizza has the best wings in New Jersey.

  • 01:00

    NEW BIOTECH AIMS TO UNLOCK THE GUT-BRAIN AXIS OF COMMUNICATION

    in Nutrition

    SOMETHING THAT WE HAVE BEEN DISCUSSING FOR A DECADE NOW..THAT THE BRAIN TALKS TO THE GUT AND VICE VERSA...FROM AS EARLY AS 4 WEEKS OF AGE. AND THE MAINTENANCE OF THAT COMMUNICATION PATHWAY COULD BE THE ULTIMATE LINK TO GOOD HEALTH?  TUNE IN.


    Tune in every day to hear Dr. Len Brancewicz of The Nutrition Shoppe
    discuss today's hottest health topics and news from a complimentary
    perspective.  From colds to cancer and everything in between, Dr. Len
    can offer honest advice that makes sense.

    As a Registered Pharmacist (RPh), Certified Clinical Nutritionist (CCN),
    Doctor of Naturopathic Medicine (NMD), and a homeopath, Dr. Len has over
    35 years experience in helping to keep you and your family healthy and
    happy.
    Call the show today to ask about your most pressing health concerns!

    Visit us on the web at www.TheNutritionShoppe.net or call toll free at
    866-461-4536866-461-4536 FREE to set up a personalized consultation, shop products, or
    ask questions!

  • 02:05

    The Health and Wellness Show - 18 Dec 2015 - Health and Wellness Yearly Roundup

    in Health

    This week on the Health and Wellness Show, we take a look back at some of the headline events of 2015 in health. Mandatory vaccination creeping ever closer, Big Biotech further cementing their position on GMOs, the WHO declaring red meat to be carcinogenic and Big Pharma price gouging were some of the big events in the world of health this year. We'll be covering these and looking at some of the updates as things continue to unfold. We'll also be looking at some of the positives that happened as more and more people seem to be waking up to the terror of the situation - saturated fat being redeemed, the truth about cholesterol seeing the light of day, the keto diet gaining wider acceptance, new developments in understanding autoimmune conditions and people power popping up in the fight against Big Pharma and mandatory vaccination.


    Join us every Friday at 10am EST as we expose the lies and emphasize the truth about health in our modern world. With us as always will be Zoya with her Pet Health Segment.

  • 00:17

    Healthcare: How To Evaluate Healthcare M&A Deals

    in Finance

    On this episode, Motley Fool analysts explain how to break down biotech mergers and acquisitions.

  • 00:33

    Leveraging Loopholes: Biotech's Answer to Consumer GMO Protest

    in News

    One of the latest practices in biotech is a process that allows DNA to be edited down to the letter. Known as CRISPR technology, scientists now have the ability to control gene mechanisms with unprecedented accuracy and without traditional invasive high-cost GMO procedures as they exist now. In effect, CRISPR is the evolution of GMO. All of this allows corporations to continue producing genetically altered foods without ever having to worry about legislation or labeling mandates. As consumer "right to know" demand increases and more companies are responding to protests by voluntarily labeling GMO products or removing them from their ingredients altogether, industry is well ahead of the game and consumers should not be fooled into complacency. CRISPR technology allows a crafty bypass because it is not recognized technically as a GMO process as is currently defined. Industry can use this technology to dodge existing regulations now, or in the future, and avoid GMO stigmas in public perception as they continue driving corporate profit. They would not have to disclose this new process to regulators or the public, rendering the hotly debated GMO labeling issue effectively moot. Present day loopholes in an obsolete agribusiness regulatory system may be the biggest challenge yet as consumers fight to stay informed and aware of what is happening to the manufacturing of food. Is CRISPR technology the ultimate bait and switch in the GMO debate?

  • 00:44

    ​STEM EDUCATION​: PUBLIC/PRIVATE PARTNERSHIPS & THE AMGEN FOUNDATION

    in Education

    STEM EDUCATION: PUBLIC/PRIVATE PARTNERSHIPS & THE AMGEN FOUNDATION


    AMGEN FOUNDATION  V.P.  Scott Heimlich  is joined by educator Winnie Litten. Advanced Honors and Biology Teacher at Oak Park HS in Oak Park ,CA, one of the first teacher to participate in The Amgen BioTech Experience.


    Presented by LEGO EDUCATION

  • 01:08

    How She Paid Down $70,000 In Debt

    in Business

    Tanya Thomas had LOTS of debt and struggled to pay it off...but came out triumphant. How did she accumulate so much debt? What was her low point? How did she pay it off? What tools did she use? What can she do now that it's gone? She'll explain everything on today's show!

    In our letters segment we discuss biotech. It's been low for awhile now. Is it a buy? Also, OG & Joe tackle headlines about a stealthy financial firm and another about family financial planning issues. That and much more happen on today's show.

    Thanks to SoFi and MagnifyMoney.com for sponsoring our podcast!

  • 00:43

    How She Paid Down $70,000 In Debt

    in Business

    Tanya Thomas had LOTS of debt and struggled to pay it off...but came out triumphant. How did she accumulate so much debt? What was her low point? How did she pay it off? What tools did she use? What can she do now that it's gone? She'll explain everything on today's show!

    In our letters segment we discuss biotech. It's been low for awhile now. Is it a buy? Also, OG & Joe tackle headlines about a stealthy financial firm and another about family financial planning issues. That and much more happen on today's show.

    Thanks to SoFi and MagnifyMoney.com for sponsoring our podcast!

  • 00:31

    Genetically Modified: The Biotech World - Here and Now

    in News

    What are the latest developments in the world of GMOs? From GMO labeling laws, global outrage, corporate product pipelines, to the debacle over the Seralini study on human health risks, we will examine new aspects to the biotech business and their implications for the health and safety of consumers worldwide. We may know where we have been and we may know where we are in the midst of the genetically modified debate, but can we see where we are going?